Amylyx Pharmaceuticals Key Executives
This section highlights Amylyx Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Amylyx Pharmaceuticals
(Showing 0 of )
Amylyx Pharmaceuticals Earnings
This section highlights Amylyx Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-04 | $-0.49 | $-0.55 |
| Read Transcript | Q3 | 2024 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-09 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $0.24 | $-0.46 |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $0.23 | $0.07 |
| Read Transcript | Q3 | 2023 | 2023-11-11 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $0.10 | $0.31 |
| Read Transcript | Q1 | 2023 | 2023-05-11 | $-0.24 | $0.02 |
Financial Statements
Access annual & quarterly financial statements for Amylyx Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $87.37M | $380.79M | $22.23M | $285.00K | $650.00K |
| Cost of Revenue | $42.16M | $25.44M | $2.99M | $52.00K | $24.59M |
| Gross Profit | $45.22M | $355.35M | $19.24M | $233.00K | $-23.94M |
| Gross Profit Ratio | 51.75% | 93.32% | 86.54% | 81.75% | -3683.69% |
| Research and Development Expenses | $104.08M | $128.19M | $93.45M | $44.04M | $24.59M |
| General and Administrative Expenses | $- | $178.86M | $127.13M | $38.93M | $15.06M |
| Selling and Marketing Expenses | $- | $9.50M | $4.40M | $- | $- |
| Selling General and Administrative Expenses | $114.33M | $188.36M | $127.13M | $38.93M | $15.06M |
| Other Expenses | $141.53M | $- | $3.74M | $-285.00K | $-650.00K |
| Operating Expenses | $359.95M | $316.54M | $220.58M | $82.69M | $39.01M |
| Cost and Expenses | $402.10M | $341.98M | $223.57M | $82.69M | $39.01M |
| Interest Income | $13.81M | $16.16M | $4.29M | $36.00K | $14.00K |
| Interest Expense | $- | $- | $4.29M | $- | $2.29M |
| Depreciation and Amortization | $904.00K | $1.09M | $487.00K | $52.00K | $1.00K |
| EBITDA | $-290.98M | $39.89M | $-200.85M | $-82.64M | $-39.00M |
| EBITDA Ratio | -333.03% | 10.48% | -903.53% | -28995.09% | -6000.62% |
| Operating Income | $-314.73M | $38.80M | $-201.34M | $-82.69M | $-39.01M |
| Operating Income Ratio | -360.22% | 10.19% | -905.72% | -29013.33% | -6000.77% |
| Total Other Income Expenses Net | $12.60M | $15.49M | $3.74M | $-5.24M | $-3.27M |
| Income Before Tax | $-302.14M | $54.30M | $-197.60M | $-87.93M | $-42.28M |
| Income Before Tax Ratio | -345.81% | 14.26% | -888.89% | -30852.98% | -6504.62% |
| Income Tax Expense | $-393.00K | $5.03M | $774.00K | $-52.00K | $2.56M |
| Net Income | $-301.74M | $49.27M | $-198.38M | $-87.88M | $-44.84M |
| Net Income Ratio | -345.36% | 12.94% | -892.38% | -30834.74% | -6898.00% |
| EPS | $-4.43 | $0.73 | $-2.98 | $-1.52 | $-0.79 |
| EPS Diluted | $-4.43 | $0.70 | $-2.98 | $-1.52 | $-0.79 |
| Weighted Average Shares Outstanding | 68.14M | 67.23M | 66.51M | 57.86M | 56.47M |
| Weighted Average Shares Outstanding Diluted | 68.14M | 69.99M | 66.51M | 57.86M | 56.47M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $-665.00K | $416.00K | $-1.02M | $88.64M | $108.45M | $102.69M | $98.22M | $71.43M | $21.89M | $345.00K | $- | $- | $- | $285.00K | $- | $- | $350.00K |
| Cost of Revenue | $- | $809.00K | $7.63M | $116.72M | $9.36M | $5.22M | $5.58M | $5.28M | $2.82M | $172.00K | $105.00K | $35.00K | $22.00K | $12.85M | $10.00K | $10.00K | $5.01M |
| Gross Profit | $-665.00K | $-393.00K | $-8.65M | $-28.08M | $99.09M | $97.47M | $92.64M | $66.14M | $19.06M | $173.00K | $-105.00K | $-35.00K | $-22.00K | $-12.57M | $-10.00K | $-10.00K | $-4.66M |
| Gross Profit Ratio | 100.00% | -94.47% | 845.46% | -31.68% | 91.37% | 94.92% | 94.32% | 92.60% | 87.11% | 50.14% | - | - | - | -4409.82% | - | - | -1332.29% |
| Research and Development Expenses | $22.89M | $21.24M | $23.14M | $36.29M | $44.91M | $30.04M | $29.04M | $24.19M | $22.81M | $24.91M | $24.26M | $21.46M | $13.39M | $12.85M | $10.93M | $6.86M | $5.01M |
| General and Administrative Expenses | $- | $- | $- | $57.76M | $42.74M | $48.72M | $43.39M | $44.01M | $56.34M | $29.94M | $29.99M | $26.35M | $14.92M | $10.35M | $7.66M | $6.00M | $3.93M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $9.50M | $- | $- | $- | $-15.50M | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $17.10M | $17.83M | $21.65M | $57.76M | $52.24M | $48.72M | $43.39M | $44.01M | $40.84M | $29.94M | $29.99M | $26.35M | $14.92M | $10.35M | $7.66M | $6.00M | $3.93M |
| Other Expenses | $- | $36.20M | $-483.00K | $-747.00K | $171.00K | $-488.00K | $-81.00K | $3.46M | $2.47M | $199.00K | $-42.00K | $-19.00K | $-59.00K | $-227.00K | $-3.34M | $-1.66M | $1.00K |
| Operating Expenses | $39.99M | $75.27M | $44.79M | $94.05M | $97.16M | $78.75M | $72.44M | $68.20M | $63.66M | $54.85M | $54.25M | $47.81M | $28.32M | $22.92M | $18.59M | $12.87M | $8.59M |
| Cost and Expenses | $39.99M | $76.08M | $52.41M | $210.77M | $106.52M | $83.97M | $78.02M | $73.48M | $66.48M | $55.03M | $54.25M | $47.81M | $28.32M | $22.92M | $18.59M | $12.87M | $8.59M |
| Interest Income | $2.32M | $3.10M | $4.07M | $4.33M | $4.37M | $4.18M | $3.89M | $3.72M | $3.16M | $601.00K | $402.00K | $131.00K | $30.00K | $3.00K | $1.00K | $2.00K | $- |
| Interest Expense | $- | $- | $- | $- | $3.46M | $- | $- | $- | $3.16M | $601.00K | $402.00K | $131.00K | $30.00K | $3.00K | $1.00K | $2.00K | $1.00K |
| Depreciation and Amortization | $160.00K | $221.00K | $208.00K | $315.00K | $301.00K | $302.00K | $281.00K | $204.00K | $182.00K | $165.00K | $105.00K | $35.00K | $22.00K | $10.00K | $10.00K | $10.00K | $1.00K |
| EBITDA | $-40.49M | $-39.24M | $-53.23M | $-121.81M | $2.23M | $19.02M | $20.48M | $-1.85M | $-44.41M | $-54.52M | $-54.15M | $-47.78M | $-28.32M | $-22.91M | $-18.58M | $-12.86M | $-8.59M |
| EBITDA Ratio | 6089.32% | -9431.97% | 5203.04% | -137.42% | 2.06% | 18.52% | 20.85% | -2.59% | -202.93% | -15801.74% | - | - | - | -8037.89% | - | - | -2454.29% |
| Operating Income | $-40.65M | $-75.66M | $-53.44M | $-122.13M | $1.93M | $18.72M | $20.20M | $-2.05M | $-44.59M | $-54.68M | $-54.25M | $-47.81M | $-28.32M | $-22.92M | $-18.59M | $-12.87M | $-8.59M |
| Operating Income Ratio | 6113.38% | -18187.74% | 5223.37% | -137.78% | 1.78% | 18.23% | 20.57% | -2.87% | -203.76% | -15849.57% | - | - | - | -8041.40% | - | - | -2454.86% |
| Total Other Income Expenses Net | $2.47M | $2.96M | $-19.27M | $3.58M | $4.54M | $3.69M | $3.81M | $3.46M | $2.47M | $800.00K | $360.00K | $112.00K | $-29.00K | $-224.00K | $-3.33M | $-1.66M | $- |
| Income Before Tax | $-38.18M | $-72.70M | $-72.70M | $-118.55M | $6.48M | $22.41M | $24.01M | $1.40M | $-42.12M | $-53.88M | $-53.89M | $-47.70M | $-28.34M | $-23.14M | $-21.92M | $-14.52M | $-8.59M |
| Income Before Tax Ratio | 5741.50% | -17476.92% | 7106.56% | -133.74% | 5.97% | 21.82% | 24.44% | 1.96% | -192.48% | -15617.68% | - | - | - | -8120.00% | - | - | -2454.86% |
| Income Tax Expense | $-635.00K | $- | $- | $242.00K | $1.75M | $1.52M | $1.93M | $-170.00K | $579.00K | $-125.00K | $174.00K | $146.00K | $-30.00K | $221.00K | $3.33M | $1.65M | $2.00K |
| Net Income | $-37.55M | $-72.70M | $-72.70M | $-118.79M | $4.73M | $20.89M | $22.07M | $1.57M | $-42.70M | $-53.76M | $-54.07M | $-47.85M | $-28.34M | $-23.14M | $-21.92M | $-14.52M | $-8.59M |
| Net Income Ratio | 5646.02% | -17476.92% | 7106.56% | -134.01% | 4.36% | 20.35% | 22.47% | 2.20% | -195.13% | -15581.45% | - | - | - | -8120.00% | - | - | -2454.86% |
| EPS | $-0.55 | $-1.07 | $-1.07 | $-1.75 | $0.07 | $0.31 | $0.33 | $0.02 | $-0.65 | $-0.92 | $-0.93 | $-0.93 | $-0.51 | $-0.42 | $-0.48 | $-0.32 | $-0.19 |
| EPS Diluted | $-0.55 | $-1.07 | $-1.07 | $-1.75 | $0.07 | $0.30 | $0.31 | $0.02 | $-0.65 | $-0.92 | $-0.93 | $-0.93 | $-0.51 | $-0.42 | $-0.48 | $-0.32 | $-0.19 |
| Weighted Average Shares Outstanding | 68.59M | 68.09M | 68.02M | 67.85M | 67.41M | 67.41M | 67.23M | 66.72M | 65.42M | 58.53M | 58.14M | 51.45M | 55.22M | 55.22M | 45.95M | 45.95M | 45.95M |
| Weighted Average Shares Outstanding Diluted | 68.59M | 68.09M | 68.02M | 67.85M | 69.20M | 69.75M | 70.13M | 70.86M | 65.42M | 58.53M | 58.28M | 51.60M | 55.22M | 55.22M | 45.95M | 45.95M | 45.95M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $77.39M | $170.20M | $62.53M | $50.19M | $12.88M |
| Short Term Investments | $99.11M | $201.16M | $284.42M | $45.93M | $- |
| Cash and Short Term Investments | $176.50M | $371.36M | $346.94M | $96.12M | $12.88M |
| Net Receivables | $447.00K | $40.05M | $15.31M | $- | $- |
| Inventory | $- | $38.32M | $9.77M | $- | $- |
| Other Current Assets | $12.48M | $14.93M | $10.11M | $8.83M | $762.00K |
| Total Current Assets | $189.43M | $464.67M | $382.13M | $101.51M | $13.64M |
| Property Plant Equipment Net | $2.73M | $6.41M | $8.13M | $474.00K | $151.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $719.00K | $189.00K | $189.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.47M | $46.38M | $466.00K | $3.44M | $125.00K |
| Total Non-Current Assets | $4.20M | $52.79M | $9.32M | $4.10M | $465.00K |
| Other Assets | $- | $- | $1 | $1 | $1 |
| Total Assets | $193.63M | $517.45M | $391.45M | $105.61M | $14.10M |
| Account Payables | $2.94M | $22.06M | $6.26M | $4.37M | $3.61M |
| Short Term Debt | $1.52M | $2.26M | $4.08M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $23.95M | $57.72M | $36.27M | $13.02M | $3.71M |
| Total Current Liabilities | $28.41M | $82.04M | $46.61M | $17.40M | $7.33M |
| Long Term Debt | $463.00K | $1.98M | $4.24M | $- | $1.43M |
| Deferred Revenue Non-Current | $- | $- | $- | $35.00K | $14.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $35.00K | $72.06M |
| Total Non-Current Liabilities | $463.00K | $1.98M | $4.24M | $239.39M | $73.50M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $28.87M | $84.02M | $50.85M | $256.78M | $80.83M |
| Preferred Stock | $- | $- | $391.45M | $7.67M | $72.06M |
| Common Stock | $7.00K | $7.00K | $7.00K | $1.00K | $1.00K |
| Retained Earnings | $-606.69M | $-304.95M | $-354.22M | $-155.84M | $-67.91M |
| Accumulated Other Comprehensive Income Loss | $-92.00K | $197.00K | $-86.00K | $9.00K | $-72.06M |
| Other Total Stockholders Equity | $771.54M | $738.18M | $694.91M | $244.02M | $1.19M |
| Total Stockholders Equity | $164.76M | $433.43M | $340.61M | $-151.17M | $-66.72M |
| Total Equity | $164.76M | $433.43M | $340.61M | $-151.17M | $-66.72M |
| Total Liabilities and Stockholders Equity | $193.63M | $517.45M | $391.45M | $105.61M | $14.10M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $193.63M | $517.45M | $391.45M | $105.61M | $14.10M |
| Total Investments | $99.11M | $201.16M | $284.42M | $45.93M | $189.00K |
| Total Debt | $1.98M | $4.24M | $6.28M | $- | $1.43M |
| Net Debt | $-75.41M | $-165.96M | $-56.25M | $-50.19M | $-11.45M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $77.39M | $71.84M | $75.00M | $170.55M | $170.20M | $135.26M | $247.76M | $114.56M | $62.53M | $107.73M | $67.44M | $110.40M | $50.19M | $76.68M | $-12.88M | $12.88M |
| Short Term Investments | $99.11M | $162.56M | $234.81M | $202.74M | $201.16M | $219.79M | $109.52M | $231.11M | $284.42M | $54.86M | $139.24M | $144.80M | $45.93M | $49.02M | $25.75M | $- |
| Cash and Short Term Investments | $176.50M | $234.40M | $309.81M | $373.29M | $371.36M | $355.05M | $357.28M | $345.67M | $346.94M | $162.59M | $206.68M | $255.21M | $96.12M | $125.70M | $12.88M | $12.88M |
| Net Receivables | $447.00K | $1.73M | $4.09M | $20.35M | $40.05M | $29.35M | $33.47M | $17.55M | $15.31M | $137.00K | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $38.32M | $32.37M | $24.86M | $13.07M | $9.77M | $563.00K | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $12.48M | $9.14M | $12.82M | $16.89M | $14.93M | $17.34M | $11.79M | $12.75M | $10.11M | $8.91M | $18.92M | $20.57M | $8.83M | $4.24M | $- | $762.00K |
| Total Current Assets | $189.43M | $245.26M | $326.72M | $410.53M | $464.67M | $434.11M | $427.39M | $389.05M | $382.13M | $171.63M | $216.14M | $265.49M | $101.51M | $129.94M | $12.88M | $13.64M |
| Property Plant Equipment Net | $2.73M | $3.53M | $4.24M | $5.71M | $6.41M | $6.95M | $7.28M | $7.65M | $8.13M | $8.07M | $8.23M | $8.07M | $474.00K | $329.00K | $- | $151.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $719.00K | $719.00K | $719.00K | $25.05M | $18.45M | $10.79M | $719.00K | $719.00K | $419.00K | $419.00K | $189.00K | $- | $- | $189.00K |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.47M | $1.92M | $479.00K | $493.00K | $45.66M | $476.00K | $466.00K | $466.00K | $466.00K | $1.03M | $456.00K | $456.00K | $3.44M | $189.00K | $-12.88M | $125.00K |
| Total Non-Current Assets | $4.20M | $5.45M | $5.44M | $6.92M | $52.79M | $32.47M | $26.19M | $18.91M | $9.32M | $9.81M | $9.10M | $8.95M | $4.10M | $518.00K | $-12.88M | $465.00K |
| Other Assets | $- | $- | $1 | $- | $- | $1 | $- | $- | $1 | $- | $- | $1 | $1 | $- | $- | $1 |
| Total Assets | $193.63M | $250.71M | $332.16M | $417.46M | $517.45M | $466.58M | $453.59M | $407.96M | $391.45M | $181.44M | $225.24M | $274.44M | $105.61M | $130.46M | $- | $14.10M |
| Account Payables | $2.94M | $1.49M | $4.96M | $21.45M | $22.06M | $6.37M | $24.70M | $10.77M | $6.26M | $7.05M | $8.12M | $10.04M | $4.37M | $3.03M | $- | $3.61M |
| Short Term Debt | $1.52M | $1.97M | $2.37M | $4.62M | $4.51M | $4.40M | $2.15M | $4.19M | $2.04M | $3.98M | $3.57M | $2.81M | $- | $263.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $23.95M | $50.46M | $62.76M | $65.56M | $55.47M | $34.84M | $37.24M | $36.66M | $38.31M | $21.61M | $15.47M | $14.85M | $13.02M | $11.86M | $- | $3.71M |
| Total Current Liabilities | $28.41M | $53.91M | $70.08M | $91.64M | $82.04M | $45.62M | $64.08M | $49.52M | $46.61M | $32.65M | $27.16M | $27.71M | $17.40M | $15.15M | $- | $7.33M |
| Long Term Debt | $463.00K | $595.00K | $772.00K | $1.38M | $1.98M | $2.57M | $3.14M | $3.69M | $4.24M | $4.77M | $5.29M | $5.79M | $- | $- | $- | $1.43M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $35.00K | $31.00K | $- | $14.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.17M |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $35.00K | $239.35M | $- | $69.89M |
| Total Non-Current Liabilities | $463.00K | $595.00K | $772.00K | $1.38M | $1.98M | $2.57M | $3.14M | $5.79M | $4.24M | $4.77M | $5.29M | $5.79M | $239.39M | $239.38M | $- | $73.50M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $28.87M | $54.51M | $70.85M | $93.02M | $84.02M | $48.18M | $67.22M | $55.31M | $50.85M | $37.41M | $32.45M | $33.49M | $256.78M | $254.53M | $- | $80.83M |
| Preferred Stock | $- | $- | $- | $- | $517.45M | $466.58M | $453.59M | $407.96M | $- | $181.44M | $225.24M | $274.44M | $239.35M | $239.35M | $72.06M | $72.06M |
| Common Stock | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $6.00K | $1.00K | $1.00K | $- | $1.00K |
| Retained Earnings | $-606.69M | $-569.15M | $-496.44M | $-423.74M | $-304.95M | $-309.68M | $-330.57M | $-352.65M | $-354.22M | $-311.52M | $-257.76M | $-203.69M | $-155.84M | $-127.50M | $- | $-67.91M |
| Accumulated Other Comprehensive Income Loss | $-92.00K | $641.00K | $-97.00K | $-77.00K | $197.00K | $-151.00K | $-72.00K | $25.00K | $-86.00K | $-725.00K | $-196.00K | $-151.00K | $9.00K | $-1.00K | $-66.72M | $-72.06M |
| Other Total Stockholders Equity | $771.54M | $764.70M | $757.84M | $748.25M | $738.18M | $728.22M | $717.00M | $705.26M | $694.91M | $456.26M | $450.74M | $444.78M | $4.67M | $-235.92M | $-1 | $1.19M |
| Total Stockholders Equity | $164.76M | $196.20M | $261.31M | $324.44M | $433.43M | $418.40M | $386.37M | $352.65M | $340.61M | $144.03M | $192.79M | $240.95M | $-151.17M | $-124.07M | $5.34M | $-66.72M |
| Total Equity | $164.76M | $196.20M | $261.31M | $324.44M | $433.43M | $418.40M | $386.37M | $352.65M | $340.61M | $144.03M | $192.79M | $240.95M | $-151.17M | $-124.07M | $5.34M | $-66.72M |
| Total Liabilities and Stockholders Equity | $193.63M | $250.71M | $332.16M | $417.46M | $517.45M | $466.58M | $453.59M | $407.96M | $391.45M | $181.44M | $225.24M | $274.44M | $105.61M | $130.46M | $5.34M | $14.10M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $193.63M | $250.71M | $332.16M | $417.46M | $517.45M | $466.58M | $453.59M | $407.96M | $391.45M | $181.44M | $225.24M | $274.44M | $105.61M | $130.46M | $5.34M | $14.10M |
| Total Investments | $99.11M | $162.56M | $235.53M | $203.46M | $201.16M | $219.79M | $109.52M | $231.11M | $284.42M | $54.86M | $139.24M | $144.80M | $45.93M | $49.02M | $25.75M | $189.00K |
| Total Debt | $1.98M | $2.57M | $3.14M | $3.69M | $4.24M | $4.77M | $5.29M | $5.79M | $6.28M | $6.76M | $7.07M | $7.19M | $- | $263.00K | $- | $1.43M |
| Net Debt | $-75.41M | $-69.27M | $-71.86M | $-166.86M | $-165.96M | $-130.49M | $-242.47M | $-108.78M | $-56.25M | $-100.98M | $-60.37M | $-103.21M | $-50.19M | $-76.41M | $12.88M | $-11.45M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-301.74M | $49.27M | $-198.38M | $-87.93M | $-42.28M |
| Depreciation and Amortization | $904.00K | $1.09M | $487.00K | $52.00K | $1.00K |
| Deferred Income Tax | $- | $- | $- | $121.00K | $1.00M |
| Stock Based Compensation | $33.04M | $37.16M | $21.71M | $3.14M | $243.00K |
| Change in Working Capital | $- | $-65.66M | $-1.64M | $4.59M | $2.60M |
| Accounts Receivables | $39.60M | $- | $-15.31M | $- | $- |
| Inventory | $-9.25M | $- | $-9.77M | $- | $- |
| Accounts Payables | $-19.10M | $15.88M | $1.85M | $670.00K | $1.42M |
| Other Working Capital | $- | $-81.54M | $21.58M | $3.92M | $1.18M |
| Other Non Cash Items | $100.15M | $-9.94M | $-2.06M | $5.23M | $1.74M |
| Net Cash Provided by Operating Activities | $-167.65M | $11.92M | $-179.87M | $-74.80M | $-36.70M |
| Investments in Property Plant and Equipment | $-157.00K | $-1.24M | $-2.53M | $-353.00K | $-151.00K |
| Acquisitions Net | $- | $- | $236.46M | $-3.00M | $- |
| Purchases of Investments | $-231.99M | $-300.83M | $-415.87M | $-49.05M | $- |
| Sales Maturities of Investments | $344.00M | $394.12M | $179.41M | $3.00M | $- |
| Other Investing Activities | $-36.20M | $- | $-236.46M | $3.00M | $- |
| Net Cash Used for Investing Activities | $75.65M | $92.05M | $-238.99M | $-46.41M | $-151.00K |
| Debt Repayment | $- | $- | $- | $25.90M | $16.82M |
| Common Stock Issued | $- | $6.86M | $432.45M | $135.00M | $30.01M |
| Common Stock Repurchased | $- | $-3.31M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $348.00K | $3.54M | $-658.00K | $132.61M | $30.01M |
| Net Cash Used Provided by Financing Activities | $348.00K | $3.54M | $431.79M | $158.51M | $46.82M |
| Effect of Forex Changes on Cash | $-438.00K | $160.00K | $-65.00K | $13.00K | $- |
| Net Change in Cash | $-92.08M | $107.67M | $12.87M | $37.31M | $9.97M |
| Cash at End of Period | $78.84M | $170.92M | $63.24M | $50.38M | $13.07M |
| Cash at Beginning of Period | $170.92M | $63.24M | $50.38M | $13.07M | $3.09M |
| Operating Cash Flow | $-167.65M | $11.92M | $-179.87M | $-74.80M | $-36.70M |
| Capital Expenditure | $-157.00K | $-1.24M | $-2.53M | $-353.00K | $-151.00K |
| Free Cash Flow | $-167.80M | $10.68M | $-182.40M | $-75.15M | $-36.85M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-37.55M | $-72.70M | $-72.70M | $-118.79M | $4.73M | $20.89M | $22.07M | $1.57M | $-42.70M | $-53.76M | $-54.07M | $-47.85M | $-28.34M | $-23.14M | $-21.92M | $-14.52M | $-8.59M |
| Depreciation and Amortization | $160.00K | $221.00K | $208.00K | $315.00K | $301.00K | $302.00K | $281.00K | $204.00K | $182.00K | $165.00K | $105.00K | $35.00K | $22.00K | $10.00K | $10.00K | $10.00K | $1.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-59.59M | $- | $- | $- | $- |
| Stock Based Compensation | $6.74M | $6.80M | $9.57M | $9.92M | $9.53M | $10.18M | $9.95M | $7.50M | $6.09M | $5.52M | $5.71M | $4.39M | $1.09M | $802.00K | $657.00K | $586.00K | $121.00K |
| Change in Working Capital | $-26.70M | $8.53M | $-8.70M | $164.00K | $1.56M | $-34.06M | $-21.71M | $-11.45M | $-11.41M | $5.08M | $1.90M | $2.79M | $-1.11M | $1.44M | $4.90M | $-634.00K | $-418.00K |
| Accounts Receivables | $980.00K | $2.24M | $16.26M | $19.70M | $-10.70M | $4.12M | $-15.92M | $-2.25M | $-15.17M | $-137.00K | $-12.00K | $-1.00K | $- | $- | $- | $-2.00K | $- |
| Inventory | $- | $- | $- | $-9.25M | $-26.48M | $-14.01M | $-19.33M | $-13.30M | $-9.21M | $-563.00K | $12.00K | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.47M | $-3.49M | $-16.43M | $-652.00K | $15.82M | $-18.39M | $13.84M | $4.61M | $-800.00K | $-1.10M | $-1.26M | $5.02M | $1.39M | $156.00K | $-1.05M | $177.00K | $466.00K |
| Other Working Capital | $-29.16M | $9.78M | $-8.52M | $-9.63M | $22.91M | $-5.77M | $-306.00K | $10.94M | $13.77M | $6.88M | $3.17M | $-2.23M | $-2.50M | $1.29M | $5.95M | $-811.00K | $-884.00K |
| Other Non Cash Items | $-1.66M | $15.58M | $15.20M | $108.66M | $-2.57M | $-2.48M | $-1.98M | $-2.90M | $-1.86M | $-89.00K | $-109.00K | $2.00K | $59.69M | $23.00K | $3.31M | $1.92M | $466.00K |
| Net Cash Provided by Operating Activities | $-59.01M | $-41.57M | $-66.58M | $-489.00K | $13.55M | $-5.17M | $8.61M | $-5.07M | $-49.70M | $-43.08M | $-46.46M | $-40.63M | $-28.24M | $-20.86M | $-13.05M | $-12.64M | $-8.89M |
| Investments in Property Plant and Equipment | $-20.00K | $19.00K | $-89.00K | $-67.00K | $-356.00K | $-357.00K | $-278.00K | $-250.00K | $-620.00K | $-459.00K | $-1.10M | $-342.00K | $-186.00K | $-153.00K | $- | $-14.00K | $-151.00K |
| Acquisitions Net | $- | $- | $- | $- | $-21.28M | $107.73M | $- | $-56.24M | $227.56M | $- | $-5.57M | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $-158.87M | $-73.11M | $-126.64M | $-164.43M | $- | $-9.76M | $-261.56M | $- | $-30.43M | $-123.88M | $- | $-49.05M | $- | $- | $- |
| Sales Maturities of Investments | $65.00M | $75.00M | $130.00M | $74.00M | $147.92M | $56.70M | $123.50M | $66.00M | $34.00M | $84.50M | $36.00M | $24.91M | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-36.20M | $-28.87M | $886.00K | $21.28M | $-107.73M | $123.50M | $56.24M | $-227.56M | $84.50M | $5.57M | $-98.97M | $3.00M | $-49.05M | $- | $- | $- |
| Net Cash Used for Investing Activities | $64.98M | $38.82M | $-28.96M | $819.00K | $20.93M | $-108.09M | $123.22M | $55.99M | $-228.18M | $84.04M | $4.46M | $-99.31M | $2.81M | $-49.21M | $- | $-14.00K | $-151.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $263.00K | $- | $25.90M | $1.16M |
| Common Stock Issued | $- | $-1.49M | $47.00K | $1.45M | $347.00K | $984.00K | $2.12M | $3.40M | $231.55M | $- | $-828.00K | $200.90M | $135.00M | $- | $1.99M | $31.00K | $- |
| Common Stock Repurchased | $- | $1.33M | $-20.00K | $-1.31M | $-117.00K | $-95.00K | $-740.00K | $-2.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $110.00K | $80.00K | $27.00K | $131.00K | $230.00K | $889.00K | $1.38M | $1.04M | $612.00K | $- | $-828.00K | $-442.00K | $-1.06M | $131.39M | $1.99M | $31.00K | $16.00K |
| Net Cash Used Provided by Financing Activities | $110.00K | $80.00K | $27.00K | $131.00K | $230.00K | $889.00K | $1.38M | $1.04M | $232.16M | $- | $-828.00K | $200.46M | $-1.06M | $131.65M | $1.99M | $25.93M | $1.18M |
| Effect of Forex Changes on Cash | $-525.00K | $236.00K | $-39.00K | $-110.00K | $237.00K | $-134.00K | $-18.00K | $75.00K | $507.00K | $-369.00K | $-135.00K | $-68.00K | $9.00K | $2.00K | $2.00K | $- | $- |
| Net Change in Cash | $5.56M | $-1.72M | $-95.55M | $351.00K | $34.94M | $-112.50M | $133.20M | $52.04M | $-45.21M | $40.59M | $-42.96M | $60.44M | $-26.49M | $61.58M | $-11.05M | $13.27M | $-7.86M |
| Cash at End of Period | $78.84M | $73.28M | $75.00M | $170.55M | $170.92M | $135.98M | $248.48M | $115.28M | $63.24M | $108.45M | $67.86M | $110.82M | $50.38M | $76.87M | $15.28M | $26.34M | $13.07M |
| Cash at Beginning of Period | $73.28M | $75.00M | $170.55M | $170.20M | $135.98M | $248.48M | $115.28M | $63.24M | $108.45M | $67.86M | $110.82M | $50.38M | $76.87M | $15.28M | $26.34M | $13.07M | $20.93M |
| Operating Cash Flow | $-59.01M | $-41.57M | $-66.58M | $-489.00K | $13.55M | $-5.17M | $8.61M | $-5.07M | $-49.70M | $-43.08M | $-46.46M | $-40.63M | $-28.24M | $-20.86M | $-13.05M | $-12.64M | $-8.89M |
| Capital Expenditure | $-20.00K | $19.00K | $-89.00K | $-67.00K | $-356.00K | $-357.00K | $-278.00K | $-250.00K | $-620.00K | $-459.00K | $-1.10M | $-342.00K | $-186.00K | $-153.00K | $- | $-14.00K | $-151.00K |
| Free Cash Flow | $-59.03M | $-41.55M | $-66.67M | $-556.00K | $13.20M | $-5.53M | $8.33M | $-5.32M | $-50.32M | $-43.54M | $-47.57M | $-40.98M | $-28.43M | $-21.02M | $-13.05M | $-12.66M | $-9.04M |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
$4.90
Stock Price
$434.15M
Market Cap
123
Employees
Cambridge, MA
Location
Revenue (FY 2024)
$87.37M
-77.1% YoY
Net Income (FY 2024)
$-301.74M
-712.4% YoY
EPS (FY 2024)
$-4.43
-732.9% YoY
Free Cash Flow (FY 2024)
$-167.80M
-1671.5% YoY
Profitability
Gross Margin
51.8%
Net Margin
-345.4%
ROE
-183.1%
ROA
-155.8%
Valuation
P/E Ratio
-0.85
P/S Ratio
2.95
EV/EBITDA
-0.63
Market Cap
$434.15M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-167.65M
-1506.6% YoY
Free Cash Flow
$-167.80M
-1671.5% YoY
Balance Sheet Summary
Total Assets
$193.63M
-62.6% YoY
Total Debt
$1.98M
53.2% YoY
Shareholder Equity
$164.76M
-62.5% YoY
Dividend Overview
$0.42
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2018-03-28 | $0.42 | March 28, 18 |
| 2017-12-28 | $0.36 | December 28, 17 |
| 2017-09-28 | $0.24 | September 28, 17 |
Amylyx Pharmaceuticals Dividends
Explore Amylyx Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-1067.82x
Amylyx Pharmaceuticals Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.42 | $0.42 | March 28, 2018 | April 02, 2018 | January 25, 2018 | |
| $0.36 | $0.36 | December 28, 2017 | January 02, 2018 | ||
| $0.24 | $0.24 | September 28, 2017 | October 02, 2017 |
Amylyx Pharmaceuticals News
Read the latest news about Amylyx Pharmaceuticals, including recent articles, headlines, and updates.
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces first participant dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in people living with ALS.
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Josh Cohen - Co-CEO Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Joe Beatty - Baird Operator Good morning, my name is Jenny and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for AMLX.